Abstracts tagged "Epidemiology"

Abstract Number: 0718 • ACR Convergence 2022
Biomarkers Predict Worsening of Lumbar Spine Degeneration and Low Back Pain: The Johnston County Osteoarthritis Project
Adam Goode¹, Rebecca Cleveland², Virginia Kraus¹, Steve George¹, Kenneth Taylor³, Todd Schwartz⁴, Jordan Renner⁴, Janet Huebner¹ and Yvonne Golightly⁵, ¹Duke University, Durham, NC, ²University of North Carolina, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC, ⁴University of North Carolina- Chapel Hill, Chapel Hill, NC, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Disc space narrowing (DSN) at the intervertebral disc and vertebral osteophyte (OST) formation are two potential sources of nociceptive lower back pain (LBP). The…
Abstract Number: 1011 • ACR Convergence 2022
Trends in Fracture Rates Among Veterans with Ankylosing Spondylitis
Sali Merjanah¹, Jean Liew¹, John Bihn², Nathanael Fillmore², Nhan Do³ and Maureen Dubreuil⁴, ¹Boston University, Boston, MA, ²VA Boston Healthcare System, Boston, MA, ³VA Boston Healthcare System, Boston University School of Medicine, Boston, MA, ⁴Department of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: A meta-analysis demonstrated that the risk of vertebral fractures in Ankylosing Spondylitis (AS) is doubled compared to non-AS comparators. Increased fracture risk in AS…
Abstract Number: 1211 • ACR Convergence 2022
Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of RA Patients
Zhaohui Su¹, Lauren Stevens², Tom Brecht¹, Jessica Paulus¹ and Stefan Weiss³, ¹OM1, Inc., Boston, MA, ²OM1, Inc., Lexington, KY, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need to better…
Abstract Number: 1558 • ACR Convergence 2022
Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain
Alba Herrero-Morant¹, Carmen Alvarez Reguera², Lara Sánchez-Bilbao², David Martínez-López², guillermo Suárez-Amorin², Raúl fernández-ramón², José Luis Martín-Varillas³, Cristina Mata⁴, Miguel Ángel González-Gay⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Cantabria, Spain, ⁴Hospital Laredo, Santander, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet's disease (BD) may present with different clinical phenotypes. Ocular and Neurobehçet's Disease (NBD) are severe complications. Data on NBD epidemiology, clinical phenotype and…
Abstract Number: 1757 • ACR Convergence 2022
The Independent Impact of Gout on Mortality and Risk of Coronary Heart Disease Among Women – a Prospective Cohort Analysis of Women over 34 Years
Chio Yokose¹, natalie mccormick¹, na lu², amit johi³, Gary Curhan⁴ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Boston, MA, ³Regeneron, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: The disease burden of female gout has increased in recent years.1 However, there remains a paucity of data on female gout, despite it being…
Abstract Number: 1922 • ACR Convergence 2022
Multi-Joint Osteoarthritis Phenotypes by Race/Ethnicity and Sex: Preliminary Descriptive Data from the Johnston County Health Study
Sherwin Novin¹, Carolina Alvarez², Todd Schwartz³, Yvonne Golightly⁴ and Amanda Nelson², ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To describe phenotypes of multi-joint osteoarthritis (MJOA) definitions by race/ethnicity and sex in a community-based cohort.Methods: The Johnston County Health Study (JoCoHS) is an…
Abstract Number: 0070 • ACR Convergence 2022
Post-operative Delirium and Cognitive Impairment: An Analysis of Predictors and 120-day Outcomes in England Using the National Hip Fracture Database (NHFD)
Samuel Hawley¹, Dominic Inman², Celia Gregson¹, Michael Whitehouse¹, Antony Johansen³ and Andrew Judge¹, ¹University of Bristol, Bristol, United Kingdom, ²Northumbria Healthcare NHS Foundation Trust, Northumbria, United Kingdom, ³Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Post-operative delirium and cognitive impairment are common after hip fracture. We set out to identify risk factors and examine the association with returning home…
Abstract Number: 0535 • ACR Convergence 2022
Increase Rates of Bacterial Infection in Patients with ‘Pre-RA’
Duncan Porter¹, Sahil Jain² and Fraser Morton³, ¹Gartnavel General Hospital, Bearsden, United Kingdom, ²Gartnavel General Hospital, Glasgow, Scotland, United Kingdom, ³University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: In 'pre-RA' there is evidence of disordered immunity manifest by the presence of auto-antibodies, increased concentration of pro-inflammatory cytokines (e.g. TNF) and acute phase…
Abstract Number: 0719 • ACR Convergence 2022
Effect of Patient-reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice
Lauren Stevens¹, Kyra Mulder², Zhaohui Su², Pam Kumparatana², Jessica Paulus² and Stefan Weiss³, ¹OM1, Inc., Lexington, KY, ²OM1, Inc., Boston, MA, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: Patient-reported outcomes (PROs) are being increasingly utilized in clinical trials to assess the impact of treatment on symptom control and patient quality of life.…
Abstract Number: 1024 • ACR Convergence 2022
Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance
Philipp Sewerin¹, stephanie Knippschild², Sabrina Tulka², Xenofon Baraliakos³ and Ralph Brinks², ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Chair for Medical Biometry and Epidemiology, Witten, Germany, ³Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Recently, we have reported an increase in the incidence and prevalence of patients with PsA in Germany based on claim data from 65 million…
Abstract Number: 1213 • ACR Convergence 2022
Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021
Joyce (Yun-Ting) Huang¹, David Jenkins², Belay Birlie Yimer¹, Jose Benitez-Aurioles², Niels Peek², Mark Lunt¹, Will Dixon³ and Meghna Jani¹, ¹Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, ²Division of Informatics, The University of Manchester, Manchester, United Kingdom, ³The University of Manchester, Manchester, United Kingdom
Background/Purpose: Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of…
Abstract Number: 1569 • ACR Convergence 2022
Lung Involvement in VEXAS Syndrome
Marta Casal Moura¹, Misbah Baqir¹, Yasmeen Tandon², Matthew J. Samec³, Kaaren K. Reichard⁴, Abhishek Mangaonkar⁵, Ronald S. Go⁵, Kenneth J. Warrington⁶, Mrinal Patnaik⁷, Matthew J. Koster⁶ and Jay H. Ryu¹, ¹Mayo Clinic, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Rochester, USA, Rochester, ²Mayo Clinic, Radiology, Rochester, USA, Rochester, ³Mayo Clinic, Division of Rheumatology, Department of Medicine, Rochester, USA, Rochester, ⁴Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, USA, Rochester, ⁵Mayo Clinic, Division of Hematology, Department of Medicine, Rochester, USA, Rochester, ⁶Mayo Clinic, ROCHESTER, MN, ⁷Mayo Clinic, Division of Hematology, Department of Medicine, Rochester, United States of America, Rochester
Background/Purpose: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a recently identified disorder caused by somatic mutations in the UBA1 gene of myeloid cells.…
Abstract Number: 1767 • ACR Convergence 2022
Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
Bernhard Hellmich¹, Konstantin Neukirch², Marco Lukas², Martin Wernitz², Dominik Beier³ and Dennis Häckl⁴, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²GlaxoSmithKline GmbH & Co. KG, Munich, Germany, ³InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany, ⁴WIG2 GmbH, Leipzig, Germany
Background/Purpose: EGPA and HES are rare multisystemic diseases associated with eosinophilia. Robust data on the epidemiology and treatment of HES and EGPA are scarce. The…
Abstract Number: 1923 • ACR Convergence 2022
Co-fluctuations of Knee Pain Between Knees in the Same Person: Data from the Osteoarthritis Initiative (OAI)
Martin Englund¹, Tuhina Neogi² and Aleksandra Turkiewicz¹, ¹Lund University, Lund, Sweden, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Pain in knee osteoarthritis (OA) is often known to fluctuate. However, there is limed knowledge of the pain fluctuations in between knees within the…
Abstract Number: 0095 • ACR Convergence 2022
Association of Urban vs. Rural Residence with New DMARD Initiation in US Veterans with Active Rheumatoid Arthritis
Luke Desilet¹, Harlan Sayles¹, Punyasha Roul², Jennifer Barton³, Gail Kerr⁴, Kaleb Michaud¹, Ted Mikuls⁵ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³VA Portland Health Care System/OHSU, Portland, OR, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While a treat-to-target strategy is endorsed by the ACR RA Treatment Guidelines, many patient, social, and healthcare system factors make implementation of this approach…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].